Ghosh Pamela, Luque-Fernandez Miguel A, Vaidya Anand, Ma Dongdong, Sahoo Rupam, Chorev Michael, Zera Chloe, McElrath Thomas F, Williams Michelle A, Seely Ellen W, Halperin Jose A
Division of Hematology, Brigham and Women's Hospital, Boston, MA.
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, U.K.
Diabetes Care. 2017 Jul;40(7):981-984. doi: 10.2337/dc16-2598. Epub 2017 Apr 27.
Plasma glycated CD59 (pGCD59) is an emerging biomarker in diabetes. We assessed whether pGCD59 could predict the following: the results of the glucose challenge test (GCT) for screening of gestational diabetes mellitus (GDM) (primary analysis); and the diagnosis of GDM and prevalence of large for gestational age (LGA) newborns (secondary analyses).
Case-control study of 1,000 plasma samples from women receiving standard prenatal care, 500 women having a normal GCT (control subjects) and 500 women with a failed GCT and a subsequent oral glucose tolerance test (case patients).
Compared with control subjects, the median (interquartile range) pGCD59 value was 8.5-fold higher in case patients and 10-fold higher in GDM patients, as follows: control subjects 0.33 (0.19); case patients 2.79 (1.4); GDM patients 3.23 (1.43) ( < 0.001); area under the receiver operating characteristic curve 0.92. LGA prevalence was 4.3% in the lowest quartile and 13.5% in the highest quartile of pGCD59.
One pGCD59 measurement during weeks 24-28 identifies pregnancy-induced glucose intolerance with high sensitivity and specificity and can potentially identify the risk for LGA.
血浆糖化CD59（pGCD59）是糖尿病领域一种新出现的生物标志物。我们评估了pGCD59是否能够预测以下情况：用于筛查妊娠期糖尿病（GDM）的葡萄糖耐量试验（GCT）结果（主要分析）；以及GDM的诊断和大于胎龄（LGA）新生儿的患病率（次要分析）。
对1000份接受标准产前护理的女性血浆样本进行病例对照研究，其中500名女性GCT结果正常（对照对象），500名女性GCT未通过且随后进行了口服葡萄糖耐量试验（病例患者）。
与对照对象相比，病例患者的pGCD59值中位数（四分位间距）高8.5倍，GDM患者高10倍，具体如下：对照对象0.33（0.19）；病例患者2.79（1.4）；GDM患者3.23（1.43）（<0.001）；受试者工作特征曲线下面积为0.92。在pGCD59最低四分位数组中，LGA患病率为4.3%，在最高四分位数组中为13.5%。
在孕24 - 28周时检测一次pGCD59，能够以高灵敏度和特异性识别妊娠诱导的糖耐量异常，并有可能识别LGA风险。
